Showing results (311-320 of 412) with videos related to

Sort By:
Pageof 42
Molecular and Cellular Probes|November 13, 2012
High-density oligonucleotide-based resequencing assay for mutations causing syndromic and non-syndromic forms of thoracic aortic aneurysms and dissectionsUshanthine Kathiravel, Britta Keyser, Sabine Hoffjan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 31, 2014
Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cellsPetra Bacher, Olaf Kniemeyer, Janka Teutschbein, et al.
Blood|April 20, 2004
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targetsMatthias Stelljes, Robert Strothotte, Hans-Gerd Pauels, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 27, 2024
Home-based high tone therapy may alleviate chemotherapy-induced neuropathic symptoms in patients with colorectal cancer: A randomized double-blind placebo-controlled pilot evaluationRobert Wakolbinger-Habel, Matthias Reinweber, Mahmoud Alakraa, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 19, 2011
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fractionFrank Edelmann, Raoul Stahrenberg, Götz Gelbrich, et al.
Frontiers in Immunology|November 11, 2017
Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory DisordersManuel Wiesinger, Diane Stoica, Susanne Roessner, et al.
Transplantation|February 14, 2007
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effectsMatthias Stelljes, Christiane Specht, Jörn Albring, et al.
BMC Cancer|August 8, 2021
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaThomas Powles, Toni K Choueiri, Robert J Motzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumorsGeoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Allergy|April 17, 2020
TCRs with segment TRAV9-2 or a CDR3 histidine are overrepresented among nickel-specific CD4+ T cellsMarina Aparicio-Soto, Franziska Riedel, Melanie Leddermann, et al.
Pageof 42